Linatab E Tablet 10 mg + 5 mg is a combination oral antidiabetic medication that contains Empagliflozin (10 mg) and Linagliptin (5 mg). This dual-action tablet is designed to help control blood glucose levels in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient. By targeting two complementary mechanisms, Linatab E helps improve glycemic control and reduce the risk of diabetes-related complications.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor

• Dipeptidyl Peptidase-4 (DPP-4) Inhibitor

Pharmacology

Empagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. This mechanism not only lowers blood glucose levels but also contributes to weight reduction and a modest blood pressure-lowering effect.

Linagliptin inhibits DPP-4, an enzyme responsible for the degradation of incretin hormones such as GLP-1 and GIP. By preventing their breakdown, Linagliptin enhances glucose-dependent insulin secretion and reduces glucagon release, leading to improved postprandial and fasting glucose control.

The combination of these two agents provides additive glycemic effects without significantly increasing the risk of hypoglycemia, as their actions are glucose-dependent.

Indications

Linatab E Tablet is indicated for:

• Adults with type 2 diabetes mellitus who require additional glycemic control beyond diet and exercise

• Patients who may benefit from dual therapy targeting both renal glucose excretion and incretin pathways

• Often used as an adjunct to other antidiabetic therapies, including metformin, when combination therapy is needed

Dosage and Administration

• The recommended dose is one tablet (10 mg Empagliflozin + 5 mg Linagliptin) once daily, taken orally with or without food.

• Tablets should be taken at the same time each day for consistent blood glucose control.

• Dosage adjustments may be required in patients with renal impairment or other comorbidities, and treatment should be individualized by a healthcare provider.

Contraindications

• Known hypersensitivity to Empagliflozin, Linagliptin, or any component of the tablet

• Patients with type 1 diabetes mellitus or diabetic ketoacidosis

• Severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Linatab E is generally well tolerated, but some adverse effects may occur:

• Genitourinary infections such as urinary tract infection or genital mycotic infections (more common with SGLT2 inhibition)

• Hypoglycemia if used in combination with insulin or insulin secretagogues

• Gastrointestinal disturbances like nausea or diarrhea

• Rare cases of volume depletion, hypotension, or ketoacidosis

Precautions and Warnings

• Ensure adequate hydration to reduce the risk of hypotension and renal complications

• Monitor kidney function periodically during treatment

• Caution in elderly patients or those at risk of urinary tract infections

• Patients should be educated to recognize signs of genital infections or ketoacidosis

Pregnancy and Lactation

• Safety in pregnancy has not been fully established; use only if the potential benefit outweighs the risk

• Not recommended during breastfeeding

Storage Conditions

• Store in a cool, dry place below 30°C, away from direct sunlight and moisture

• Keep out of reach of children

Mode of Action

Linatab E Tablet 10 mg + 5 mg provides dual glycemic control by combining renal glucose excretion (Empagliflozin) with enhanced insulin secretion and reduced glucagon release (Linagliptin). This complementary action helps maintain fasting and postprandial glucose levels, improve overall glycemic control, and support a healthier metabolic profile in type 2 diabetes patients.